A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
Review Will Determine Whether Access To Biogen's SMA Treatment Will Be Expanded
Executive Summary
NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.
You may also be interested in...
UK Spinraza Data Review Shows Benefits Of NICE Flexibility
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
UK Rare Disease Drug Review Reform Urged As Spinraza Finally Gets NICE OK
It has taken 17 months of negotiations but soon 600-1,200 people in the UK may be able to get Biogen's spinal muscular atrophy therapy now that an access agreement has been inked.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.